DXCM - DexCom, Inc.
HWG Holdings LP acquired a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 96,427 shares of the medical device company's stock, valued at approximately $8,321,000. DexCom makes up approximately 1.9% of HWG
[url="]DEXCOM[/url], INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of [url="]Dexcom U[/url], the
SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program's largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l.
Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
[url="]DexCom, Inc.[/url] (NASDAQ: DXCM), the global leader in glucose biosensing, today released its âDexcom State of Type 2 Report: Global Access and Attitu
MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo.
DexCom, Inc. (NASDAQ: DXCM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twenty-one have issued a buy rating and two have
Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world's leading medical technology.
DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Technical indicators have turned bullish for the three stocks.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The live presentation is scheduled to begin at approximately 8:00 AM EDT and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom em.
American Capital Management Inc. bought a new stake in DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 235,152 shares of the medical device company's stock, valued at approximately $15,837,000. American Capital Management Inc.
ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
Great Lakes Advisors LLC purchased a new position in shares of DexCom, Inc. (NASDAQ: DXCM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,472 shares of the medical device company's stock, valued at approximately $369,000. Other hedge funds also recently added to